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Introduction: A postpartum diagnosis of breast cancer is an independent predictor of metastases, however the
reason is unknown. In rodents, the window of postpartum mammary gland involution promotes tumor progression,
suggesting a role for breast involution in the poor prognosis of human postpartum breast cancers. Rodent
mammary gland involution is characterized by the programmed elimination of the secretory lobules laid down in
preparation for lactation. This tissue involution process involves massive epithelial cell death, stromal remodeling,
and immune cell infiltration with similarities to microenvironments present during wound healing and tumor
progression. Here, we characterize breast tissue from premenopausal women with known reproductive histories to
determine the extent, duration and cellular mechanisms of postpartum lobular involution in women.
Methods: Adjacent normal breast tissues from premenopausal women (n = 183) aged 20 to 45 years, grouped by
reproductive categories of nulliparous, pregnant and lactating, and by time since last delivery were evaluated
histologically and by special stain for lobular area, lobular type composition, apoptosis and immune cell infiltration
using computer assisted quantitative methods.
Results: Human nulliparous glands were composed dominantly of small (approximately 10 acini per lobule) and
medium (approximately 35 acini per lobule) sized lobules. With pregnancy and lactation, a >10 fold increase in
breast epithelial area was observed compared to nulliparous cases, and lactating glands were dominated by mature
lobules (>100 acini per lobule) with secretory morphology. Significant losses in mammary epithelial area and
mature lobule phenotypes were observed within 12 months postpartum. By 18 months postpartum, lobular area
content and lobule composition were indistinguishable from nulliparous cases, data consistent with postpartum
involution facilitating regression of the secretory lobules developed in preparation for lactation. Analyses of
apoptosis and immune cell infiltrate confirmed that human postpartum breast involution is characterized by wound
healing-like tissue remodeling programs that occur within a narrowed time frame.
Conclusions: Human postpartum breast involution is a dominant tissue-remodeling process that returns the total
lobular area of the gland to a level essentially indistinguishable from the nulliparous gland. Further research is
warranted to determine whether the normal physiologic process of postpartum involution contributes to the
poor prognosis of postpartum breast cancer.* Correspondence: Schedin@ohsu.edu
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Regardless of age at child birth, women face a transient
increase in risk for breast cancer during the postpartum
period [1-7]. Clinically, cases diagnosed during or in
close proximity to pregnancy have been variably referred
to as postpartum or pregnancy-associated [1-6,8,9]. Im-
portantly, a breast cancer diagnosis in the postpartum
window confers significantly poorer outcomes, even after
adjustments for known clinical prognostic indicators
[2,10,11]. These later studies identify a postpartum diag-
nosis as an independent, poor prognostic factor for
young women, and are contrary to some expectations
that a diagnosis during pregnancy would have the poor-
est prognosis [10,12-14]. Recently, using poor prognosis
as the criteria for defining postpartum breast cancer, the
definition has been expanded to include cases diagnosed
within five years of the last childbirth [11,15]. Utilizing
this definition, it is estimated that approximately 35% or
more of all young women’s cases may be negatively im-
pacted by a recent pregnancy [11,15,16]. It is anticipated
that understanding the mechanisms of tumor promotion
that occur in the postpartum window will lead to the de-
velopment of treatment and, possibly, prevention strat-
egies specific to this vulnerable patient population [17].
In rodent models, postpartum mammary gland involution
has been identified as a key mediator of tumor progression
in the postpartum setting [17,18]. During postpartum gland
involution, 80% to 90% of the secretory mammary epithe-
lium developed in preparation for lactation undergoes apop-
tosis [19-21]. Further, programs similar to wound healing
are utilized to remodel the lactation competent rodent gland
to a non-secretory state, and include extracellular matrix re-
modeling, fibrillar collagen deposition, high matrix metallo-
proteinase activity, and recruitment of macrophages with
M2-like attributes [7,18,21-28]. Of note, tissue remodeling
involving collagen deposition and macrophage infiltration
has demonstrated tumor promotional attributes in multiple
models of breast cancer [7,17,25,28-33] and independently
predicts poor outcomes in breast cancer patients [28,34,35].
Cumulatively, these studies implicate breast remodeling as-
sociated with postpartum involution as a potential mediator
of breast cancer progression in young women [8,36].
In pre-clinical models of postpartum breast cancer, non-
steroidal anti-inflammatory drugs (NSAIDs) limited in
duration to the window of postpartum gland involution
reduce tumor growth and metastasis associated with the
involution window [17,29]. These studies suggest that an
NSAID-based intervention targeted to the physiologic
window of postpartum involution may be useful in the
treatment or prevention of postpartum breast cancer
[15,37]. One critical gap in the knowledge required for ra-
tional and safe design of such treatments for women
is the lack of a thorough understanding of human
postpartum breast involution. Here, using a cohort ofpremenopausal women with known reproductive his-
tories and undergoing breast biopsy for clinical indica-
tions, we characterize postpartum breast involution.
We address the extent, duration and cellular mecha-
nisms of the postpartum human breast to determine if
lobule regression, epithelial cell death and wound
healing-like attributes are observed similar to those de-
scribed in rodent models.
Methods
Study population and reproductive categories
Breast specimens from premenopausal women, 20- to
45-years-old, who underwent clinically indicated biop-
sies were obtained with Colorado Multiple Institution
Review Board approval (COMIRB) under two proto-
cols. One protocol was a retrospective chart review
and tissue collection only study deemed exempt from
subject consent and Health Insurance Portability and
Accountability Act (HIPPA) authorization. The other
protocol included informed written patient consent.
All cases were de-identified to the research team.
One hundred and fifty eight de-identified cases were
grouped by reproductive categories of never-been-pregnant
(n = 23), pregnant (n = 16), lactating (n = 8), up to 1 month
postpartum (n = 6), and postpartum ≤6 months (n = 9), >6
to ≤12 months (n = 5), >12 to ≤18 months (n = 5), >18
to ≤24 months (n = 20), >2 to ≤3 years (n = 7), >3 to ≤6 years
(n = 17), >6 to ≤10 years (n = 10) and >10 years (n = 25)
since last childbirth. We define never-been-pregnant as
cases with no prior evidence of an incomplete pregnancy,
which resulted in seven nulliparous cases being excluded
from subsequent analysis. The never-been-pregnant cases
are referred to as nulliparous hereafter. The final cohort
included 151 cases — 120 cancer and 31 benign and in-
cluded 118 surgical breast specimens and 33 core needle
biopsies, which cumulatively are referred to as biopsies
herein. Most analyses were performed on subsets of cases
(details given below). Self-reported demographic data in-
cluded 78% Caucasian, 15% Hispanic and 7% women from
other races. An independent validation cohort was utilized
for lobule analysis, comprised of histological slides from
Norwegian women diagnosed with breast cancer ≤40 years
of age who were nulliparous (n = 10) or uniparous >10 years
postpartum (n = 10).
Histological staining and imaging
Sections of paraffin embedded tissue (4 μm) were stained
with hematoxylin and eosin (H & E) using a Sakura H & E
autostainer (Sakura Finetek, Torrance, CA, USA). Stained
slides were scanned using an Aperio Scanscope3 system
(Aperio, Vista, CA, USA) at 20× corresponding to 0.43 μm
per pixel which enables high resolution access to the entire
tissue section via a virtual image. Images were evaluated
using Imagescope software and Aperio algorithms. Only
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trained pathologist blinded to experimental group [38],
were included in analyses. In cases with cancer, normal ad-
jacent lobules, determined by a pathologist, were analyzed a
minimum of 5 mm, but on an average of >8 mm, from the
cancer.
Lobular quantification
To quantitate breast architecture, we utilized previously
established criteria of binning lobule size into divisions
of approximately 1 to 15, >15 to 50, and >50-acini per
lobule, also referred to as types 1, 2 and 3, respectively
[39,40]. A fourth category, type 4, was identified by a
secretory morphology comprised of acini with distended
lumen filled with secretions and lined with flattened epi-
thelial cells [39]. Type 4 lobules are considered to be ter-
minally differentiated milk secreting lobules and are the
dominant type present in the lactating gland [36]. All
morphological analyses were conducted blindly with re-
spect to pathologic diagnosis, reproductive category and
patient age. For validation of the lobule type analysis, a
total of 70 cases were evaluated with a minimum of 10
normal lobules for each lobule type analyzed per case,
except in cases in which fewer than 10 lobules were
present where all available lobules were included. For
analyses determining if lobular types 1 to 4 are distin-
guishable by number of nuclei per lobule or by number
of nuclei per acinus, nuclear counts were obtained on a
subset of cases (n = 30) using JPEG formatted pictures
and image J software [41]. For studies where lobular
composition of nulliparous cases was evaluated by age,
cases were separated into age-groups of ≤30 (n = 4), >30
to ≤35 (n = 6), >35 to ≤40 (n = 9) and >40 to ≤45 years
(n = 4), and all lobules present were included in the ana-
lyses. To further investigate the effect of age on the
baseline breast morphology in this cohort, an expanded
analysis of nulliparous and >2 years postpartum cases
(≤30 (n = 12), >30 to ≤35 (n = 19), >35 to ≤40 (n = 29)
and >40 to ≤45 years (n = 22)) was performed.
To investigate the use of a single surgical specimen as
morphologically representative of the whole breast, tis-
sues from each quadrant from three cases were analyzed
for total lobular type composition and lobular area.
Moreover, to determine if lobular type composition is in-
dependent of cancer presence, lobular compositions be-
tween cancer (n = 82) and benign (n = 7) cases were
compared. For this analysis, we eliminated cases preg-
nant, lactating and those ≤24 months since the last child
birth to minimize the potential influence of pregnancy
on gland morphology. The association of lobule type
with tumor estrogen receptor (ER) status was deter-
mined using ER positive (n = 47) or ER negative (n = 24)
cases. To investigate potential influences of menstrual
cycle, initial and subsequent breast biopsies from thesame woman collected two to three weeks apart were
compared for lobular type composition (n = 12).
A detailed analysis of percent lobular area was done
on a subset of cases; nulliparous (n = 12), pregnant (n =
15), lactation (n = 8) and postpartum cases based on
time since last child birth (n = 58). Further, all 151 cases
in the young women’s cohort were analyzed for lobular
type composition. Lobular type composition for individual
cases was then compiled and compared by reproductive
categories. A corroborative analysis for comparison of
lobular composition in nulliparous and uniparous >10 years
postpartum cases was performed on an independent sam-
ple from Norway (n = 20). Also, detailed analysis compar-
ing lobule number, size and acini number per lobule
was done for nulliparous (n = 12 cases) and >2 years
parous (n = 17 cases) groups.
Immunohistochemistry and special staining
Breast tissue slides were pretreated with Dako TRIS or
EDTA antigen retrieval solution (Dako North America Inc.,
Carpinteria, CA, USA) at 120 °F under pressure for five mi-
nutes. Ki-67 was used to identify cells undergoing prolifera-
tion (1:400, Dako M7240). TACS 2TdT Fluorescein
apoptotic kit (Trevigen Inc., # 4812-30-K, Gaithers-
burg, MD, USA) was implemented to visualize apop-
totic cell death. CD45, a common leucocyte marker
which is present on the surface of nucleated hematopoietic
cells, was used for identifying all immune cells (1:200,
Dako M0701, one hour incubation) [42]. CD68, a macro-
phage lysosome-associated protein [43], was used to
identify macrophages (1:300, Dako # M0876, one hour
incubation). Immunoreactivity was detected using En-
vision + system (Dako) with 3, 3′-diaminobenzidine
used as the chromogen for all stains.
Apoptotic and immune cell quantification
To quantify apoptosis, actively involuting cases at 10 days
postpartum in the absence of lactation (n = 1), and weeks
one (n = 2), two (n = 1), four (n = 1) and six (n = 1) post-
lactation were stained for terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) positive
apoptotic cells. Ten lobules with lactational and ten lob-
ules with involutional morphology per case were ana-
lyzed and the signal quantified with Image J software.
Quantification for CD45 and CD68 was performed in 10
lobules per lobular type per case utilizing a subset of 97
and 77 cases, respectively. Modified de-convoluted Aperio
algorithms were implemented for signal quantification.
Statistical analysis
Mean and standard error were used to summarize ex-
pression levels for lobular area, lobular type compos-
ition, apoptosis and immune cell infiltration. Analysis
of variance (ANOVA) was used to compare mean
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pregnant, lactation, ≤1 month, >1 to ≤6, >6 to ≤12, >12
to ≤18, >18 to ≤24 months, ≥2 to ≤6 years, >6 to ≤10 years
and >10 years postpartum. If the overall F test was signifi-
cant, comparisons between categories were carried out. If
multiple samples were taken from the same patient, cor-
relation among the samples was taken into account during
the analysis (random effect ANOVA). Two-group t-test
was used instead of ANOVA if there were only two cat-
egories in the analysis. P-values ≤0.05 were considered sta-
tistically significant throughout the paper. SAS software
9.2 (SAS Inc. Cary, NC, USA) was used for all analyses.
Results
Method comparisons for lobule type quantification and
baseline breast composition
The breast lobular component expands and differentiates
with pregnancy and lactation transforming the relatively ru-
dimentary gland into an alveolar rich lactation-competent
structure [44]. Specifically, the human breast has been re-
ported to consist predominantly of small type 1 and 2
lobules before pregnancy, large type 3 lobules during
pregnancy and mature secretory type 4 lobules during
lactation [39]. A requisite to the study of the extent
and duration of postpartum breast involution is the
validation of morphometric methods used to characterize
breast lobular types. In our cohort of 151 premenopausal
women, 20- to 45- years-old (Additional file 1: Table S1
and Additional file 2: Table S2), wide variation in breast
lobule size between cases was evident (Figure 1A). To val-
idate that acini number reproducibly distinguishes be-
tween these observed lobule types, 70 randomly selected
cases representing all reproductive categories were scored
for acini per lobule, for a total analysis of >1,700 individual
lobules. In these cases, lobule type 1 had an average 10 ± 4
acini per lobule, type 2 had an average of 35 ± 5 acini per
lobule and type 3 had an average of 114 ± 10 acini per lob-
ule, with type 4 defined by a secretory phenotype (Table 1).
We found that the number of acini per lobule distin-
guished between lobule types 1, 2, and 3 (P <0.007), but
did not distinguish between type 3 and 4 (P = 0.92)
(Table 1 and Figure 1B). Classification of lobular types
based on mean nuclear count similarly demonstrated that
lobule types 1, 2 and 3 were distinguishable (P ≤0.0002),
but types 3 and 4 were indistinguishable (P = 0.23)
(Figure 1C). These nuclear count data also indicated
that lobule maturation of type 3 to type 4 does not in-
volve a significant increase in epithelial cell prolifera-
tion. However, evidence for direct pathways between
lobular types cannot be directly discerned from mor-
phological analysis. Further, the number of nuclei per
acinus remained constant irrespective of lobular type
(Figure 1D), suggesting that the acinus is the unit of
lobular expansion in the human breast.Measuring lobular-area is an alternative method to as-
sess lobule differentiation state. As expected, the lobular
area increased with lobular complexity, and types 2, 3 and
4 were readily identified using this method (P <0.0001)
(Figure 1E). The ability of this area-method to distinguish
between types 3 and 4 reflects the increase in type 4 size
due to milk production and secretion (Figure 1A). How-
ever, using this area-method, type 1 and 2 lobules did not
differ significantly (P = 0.11) (Figure 1E), which may be
due to a wide variation in stromal to epithelial ratios
within these smaller lobules (Figure 1F and Additional
file 3: Figure S1). Since area-analysis does not distin-
guish between lobule types 1 and 2, for subsequent
analyses, we utilized number of acini per lobule to dis-
tinguish between types 1, 2 and 3, and lactational
morphology to identify type 4.
We next investigated variation in lobule architecture
in the nulliparous group. Among our nulliparous pa-
tients (n = 23), we evaluated >550 lobules and the dom-
inant lobule types were the smaller types 1 and 2;
however, significant inter-case variation was evident.
Among nulliparous women, lobule composition ranged
from 100% to 20% type 1, 60% to 0% type 2, and 30%
to 0% type 3 (Figure 2A). Surprisingly, some type 3
lobules were present in 48% of these nulliparous cases,
demonstrating that a prior complete or incomplete
pregnancy does not appear to be required for their de-
velopment (Figure 2A). Terminally differentiated, type
4 lobules were not found in these nulliparous cases
(Figure 2A). Overall, this analysis establishes a baseline
variation in lobule composition, data required to inves-
tigate effects of pregnancy, lactation and postpartum
involution on breast lobule architecture in our young
women’s breast tissue cohort.
Effect of potential technical confounders in assessing
breast architecture
To utilize lobular composition to address questions of
extent, duration and individual variation in postpartum
breast involution, it is necessary to investigate the influ-
ence of clinical and technical parameters which may
confound lobule-type quantitation. Here, we address pa-
tient age, use of a single tissue section per case, cancer
diagnosis, biologic cancer type and potential impact of
menstrual cycle on lobular type composition. In the nul-
liparous group (n = 23 cases), patient age was not found
to significantly impact lobular type composition (P ≥0.19)
(Figure 2B), nor was age found to impact lobule type com-
position in an extended cohort (n = 82 cases) consisting of
combined nulliparous and parous cases >2 years postpar-
tum (P ≥0.18) (Figure 2C). We next addressed the use of a
single tissue specimen per case as a potential methodo-
logical limitation by performing quadrant analyses on
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Figure 1 Criteria for distinguishing between lobular types. A. H & E stained images of lobules representative of types 1 to 4 (Scale bar = 30 μm).
B. Validation of acini count per lobule to distinguish lobule types, identifying type 1 (green) as approximately 10 ± 4 acini per lobule, type 2 (yellow) as
approximately 35 ± 5 acini per lobule, type 3 (pink) as approximately 114 ± 10 acini per lobule and type 4 (blue) based on secretory morphology with
differences between types 1, 2 and 3 (*P ≤0.0007), but not types 3 and 4 (P = 0.92) (n= >1,700 lobules). C. Number of nuclei per lobule quantitated for
lobular types 1, 2 and 3 (*P ≤0.002) and types 3 and 4 (P = 0.23) (n= >230 lobules). D. Number of nuclei per acini evaluated for each lobular type
shows no statistical difference (P ≥0.07) (n= > 230 lobules). E. Lobular area distinguishes between lobules types 2, 3 and 4 (*P ≤0.0001) but not
between types 1 and 2 (P = 0.11). F. H & E stained sections showing lobule types 1 and 2 occupying approximately the same area (approximately
50,000 μm2) but categorized as different types based on the number of acini/lobule (Scale bar = 90 μm). All error bars represent standard error of the
mean (SEM).
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observed (Additional file 4: Figure S2a). Further, within
the same subject, the largest mean difference in lobuletype composition was found between the lower inner and
upper outer quadrants (Additional file 4: Figure S2a). How-
ever, a mixed effect model, which takes the correlation
Table 1 Validation of acinar count method for lobule typing
Lobule
type
Criteria for lobule type based









Type 1 12 63 759 12.6 ± 11 10 ± 4
Type 2 50 53 482 9.1 ± 8.4 35 ± 5
Type 3 80 36 226 6.3 ± 4.8 114 ± 10
Type 4 Secretory morphology 13 150 11.5 ± 9.8 128 ± 27
The average number of acini per lobule per type in the breast tissue samples evaluated (last column) are not different than published acinar numbers previously
observed in human breast tissue (second column, reference 39), validating the acinar count method for subsequent analyses.
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indicates that quadrant location is not significantly associ-
ated with the presence of lobular types (lower outer (LO)
versus lower inner (LI) (P = 0.33); upper inner (UI) versus
lower inner (LI) (P = 0.40); upper outer (UO) versus lower
inner (LI) (P = 0.25)]. Further, an aggregate analysis re-
vealed no significant morphological differences between
quadrants in these cases (P ≥0.25) (Figure 2D). To address
the potential confounder of malignancy, we compared ad-
jacent normal lobular composition of women diagnosed
with benign breast lesions to those with cancer. We found
the groups indistinguishable (P = 0.59), indicating that in
normal adjacent tissue at least 5 mm distant from the
breast cancer, the presence of cancer does not significantly
alter lobule type composition (Figure 2E). Next, we exam-
ined whether ER expressivity of the breast tumor might in-
fluence lobule composition, as variation in lobule types has
been reported between patients with luminal A and basal
breast cancers [38]. In our cohort, differences in lobule
type composition were not observed between ER posi-
tive (n = 47) and ER negative (n = 24) cases (P = 0.15)
(Figure 2F). Finally, to address the potential effect of
menstrual cycling, lobule composition for types 1, 2, 3
and 4 lobules was analyzed in initial and subsequent
biopsy tissues collected two to three weeks apart in a
subset of premenopausal women (n = 12). Although
there were small variations in lobular composition be-
tween biopsy times, no significant differences between
type 1 (P = 0.38), type 2 (P = 0.32) or type 3 (P = 0.46)
lobules were observed (Figure 2G). To summarize, in
this premenopausal cohort, lobule type composition
varies more between women of the same reproductive
category than between categories defined by patient
age, biopsied quadrant, ER expression of the tumor,
presence of breast cancer and stage of menstrual cycle.
Although, overall, the power of statistical tests is low due
to low sample size, the similarities in mean values indicate
that these specific parameters have no strong influence on
lobule type analysis in the postpartum involution window,
which is the primary objective of this study.
Evidence for postpartum involution
To determine if breast tissue developed for lactation in-
volutes during the postpartum period in women, asobserved in rodent models [7,24], we assessed lobular
area and lobular composition across nulliparous, preg-
nant, lactating and postpartum groups defined by time
since last childbirth (n = 93). Lobular area in breast tis-
sue of pregnant women (mean = 26.84, 95% confidence
interval (CI) (15.7, 37.9)) showed a five-fold increase
compared to nulliparous women (mean = 5.00, 95%CI
(-3.2, 13.2)) (P <0.0001) (Figure 3A). An additional two-
fold increase (mean = 48.4, 95%CI (35.3, 61.4)) in lobule
area occurred with lactation (P <0.0001) (Figure 3A).
However, by 18 months postpartum the lobular area of
the gland was indistinguishable from the pattern ob-
served in nulliparous women (P = 0.25). It is well docu-
mented that in addition to an increase in lobular area,
there is increased lobular complexity with pregnancy
and lactation [39,45-47] and, as expected, with preg-
nancy we found the lobular type composition to be
highly shifted to type 3 and type 4 differentiated lobules,
with evidence for further maturation to type 4 lobules
with lactation (n = 151) (Figure 3B and Additional file 4:
Figure S2b). As with lobular area, by 18 months postpar-
tum, lobular type composition of the parous group was
indistinguishable from the nulliparous group (P ≥0.65)
(Figure 3B). These data indicate complete loss of the type 3
and type 4 lobules developed for lactation within a relatively
narrow window of time. A sub-analysis of lobular type
composition in women who were 18 to 24 months post-
partum confirmed high similarity with our nulliparous
cohort (compare Figure 3C with Figure 2A). In an inde-
pendent cohort of breast tissue obtained from premeno-
pausal women from Norway, on comparing nulliparous
and >10 years postpartum categories, we found no sig-
nificant differences in lobule type composition (type 1
(P = 0.72), 2 (P = 0.81) and 3 (P = 0.47)) (Figure 3D), pro-
viding additional support for postpartum involution of
the lobules expanded during pregnancy and lactation.
Combined, these morphological data strongly suggest
that the secretory mammary epithelium developed in
preparation for lactation undergoes involution within 12
to 18 months of cessation of lactation, and further, the
regressed glandular phenotype is maintained in the ab-
sence of subsequent pregnancy. Further, analysis of
>10 year postpartum cases (n = 25) grouped by unipar-
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Figure 2 Heterogeneity in lobular composition is independent of age, breast quadrant, and presence of cancer. A. Individual lobular
composition in a cohort of nulliparous women ≤45 years of age (n = 23 cases). Among women, there is marked variation in lobule type; type 1
(green), type 2 (yellow) and type 3 (pink) (n= >550 lobules). B. Lobular composition of breast in nulliparous women does not vary by age
increments of five years (≤35 years versus ≤30 years (P = 0.89); ≤40 years versus ≤30 years (P = 0.62); ≤45 years versus ≤30 years (P = 0.19)) C. Lobular
composition in an expanded cohort excluding recently pregnant and lactating women (n = 82 cases) similarly shows lobular composition is not age
dependent (≤35 years versus ≤30 years (P = 0.35); ≤40 years versus ≤30 years (P = 0.18); ≤45 years versus ≤30 years (P = 0.34)) D. Breast quadrant
analysis from three mastectomy cases demonstrated no differences in lobular types for all quadrants (LO versus LI (P = 0.33); UI versus LI (P = 0.40); UO
versus LI (P = 0.25)). E. Lobular type composition does not vary between women who were subsequently diagnosed with cancer (n = 82 cases) or
were cancer free (n = 7 cases) (P = 0.59), or (F) by the presence (n = 47 cases) or absence (n = 24 cases) of ER expression in the adjacent
tumor (P = 0.15). G. Lobular type composition is not significantly influenced by hormonal effects of the menstrual cycle as depicted by initial
and subsequent breast biopsies two to three weeks apart (n = 12 cases) for type 1 (P = 0.38), 2 (P = 0.32) and 3 (P = 0.46) lobules. All error
bars represent standard error of the mean (SEM). LI, lower inner; LO, lower outer; UI, upper inner; UO, upper outer.
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of completed pregnancies (Additional file 5: Figure S3),
suggesting loss of differentiated lobules following each
pregnancy.
As previously reported, we also observed an increase
in proliferative capacity with pregnancy and confirmed
previous reports of decreased proliferative capacity in lob-
ules of parous compared to nulliparous lobules (Figure 4A)[39]. Subsequent morphometric analysis demonstrated an
increase in number of lobules per unit area in the parous
compared to the nulliparous gland (P = 0.04) (Figure 4B).
The observation that lobule number increases with parity
but overall area of the gland composed of lobules does not
(compare Figure 4B with Figure 3A) suggests that the fully
regressed lobules of the parous gland are smaller than in
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Figure 3 Histological evidence of postpartum involution in human breast. A. Percent lobular area by reproductive groups of nulliparous (N) (n = 12),
pregnant (P) (n = 15), lactation (L) (n = 8), up to 1 (n = 6), >1 to ≤6 (n = 9), >6 to ≤12 (n = 5), >12 to ≤18 (n = 5), >18 to ≤24 months (n = 12), >2 to ≤6 years
(n = 11) and >10 years (n = 10) since last child birth. Percent lobular area is significantly different from N during P (*P <0.0001), L (**P <0.0001), ≤1
(***P <0.0001), and at >1 to ≤6 months (****P = 0.0007) postpartum, and not statistically different at 12 months postpartum (P = 0.07). B. Breast
lobular composition across the reproductive groups of N (n = 23), P (n = 16), L (n = 8), up to 1 (n = 6), >1 to ≤6 (n = 9), >6 to ≤12 (n = 5), >12 to ≤18
(n = 5), >18 to ≤24 months (n = 20), and >2 to ≤6 (n = 24), >6 to ≤10 (n = 10) and >10 years (n = 25) since last child birth. The lobular type composition
is different from the N group during P (*P <0.001), L (**P <0.001), ≤1 month (***P <0.0001), >1 to ≤6 months (****P = 0.0001), >6 to ≤12 months
(*****P = 0.001) postpartum, and is indistinguishable by 18 months postpartum (P = 0.08). C. Lobular composition of individual women
who are >18 to ≤24 months postpartum (n = 20). D. An independent Norwegian cohort comprising Nulliparous (n = 10) and >10 years parous
(n = 10) cases shows no lobular differences between groups. Type 1 (P = 0.72), 2 (P = 0.81) and 3 (P = 0.47). All error bars represent standard error of the
mean (SEM).
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http://breast-cancer-research.com/content/16/2/R31confirmed reduced lobule size in parous compared to nul-
liparous glands (Figure 4C), which is not accounted for by
a decrease in acini number per lobule (Figure 4D). Similar
trends were observed for type 3, but not type 2 lobules
(Additional file 6: Figure S4a,b). Representative H & E im-
ages of type 1 lobules in the nulliparous gland depict re-
duced lobule number and increased lobule size in
comparison to a >24 month postpartum case (Figure 4E).
In total, these data demonstrate similarity in lobule
area and lobule type in the nulliparous and parous
cases >24 months postpartum, consistent with postpar-
tum involution, but also demonstrate decreased prolif-
erative capacity, increased number and decreased lobule
size with parity.Histological hallmarks of postpartum involution
We next investigated whether postpartum breast involu-
tion in women is characterized by increased alveolar cell
apoptosis, a well-documented hallmark of postpartum
mammary gland involution in rodents [7,18,19,23,24].
To assess for apoptosis in human involuting breast,
we identified six cases within six weeks post-weaning, as
alveolar cell apoptosis is an early involution event in ro-
dents [21,48]. Breast tissue from these cases were com-
prised of lactational, type 4 lobules as well as condensed,
non-secretory, type 3 lobules, morphologies consistent
with ongoing involution (Figure 5Aa,b). In these cases,
apoptotic cells, as assessed by immunohistochemistry
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Figure 4 Lobular differences in nulliparous and parous breast tissue. A. Significant differences in proliferative index using Ki-67 between
breast lobules of nulliparous (N) (green), pregnant (Preg) (gray) and parous >10 year (purple) women. Lobules of Nulliparous and parous
>10 years are different from Preg lobules (*P <0.0001). The inset shows there is a significant decrease in proliferative capacity in parous
breast lobules when compared to Nulliparous breast lobules (**P = 0.030). B. Lobule count data show an increase in number of lobules
per unit area in >2 years postpartum when compared to the Nulliparous breast tissue (*P = 0.04). C. The average area of type 1 lobules is
significantly increased in Nulliparous breast tissue compared to type 1 lobules in >2 years postpartum breast issue (*P = 0.04). D. No significant
differences were noted on comparing the acinar count of type 1 lobules between the Nulliparous and >2 years postpartum breast tissue (P = 0.66).
E. The H & E stained images show Nulliparous breast tissue with a reduced number of lobules per area and larger size type 1 lobules when
compared to >2 years postpartum breast tissue (Scale bar = 30 μm). All error bars represent standard error of the mean (SEM).
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http://breast-cancer-research.com/content/16/2/R31five-fold in condensed lobules compared to lobules with
a lactational phenotype (P <0.0001) (Figure 5Ac,d, 5B).
Furthermore, many individual acini contained multiple
TUNEL-positive cells (Figure 5Ad, inset). These data are
consistent with programmed cell death of the secretory
epithelium contributing, at least in part, to the dramatic
decrease in glandular tissue observed during postpartum
breast involution.
Recently, it has been observed that postpartum mam-
mary gland involution is characterized by an influx ofimmune cells thought to be integral to tumor promotion
[7,25,28,30]. For example, using human breast tissue
composed of both lactational and actively involuting lob-
ules, we previously demonstrated high levels of CD45+
leukocytes and CD68+ macrophages in lobules with an
involuting morphology [7]. However, these studies have
not identified the duration of immune cell infiltrate dur-
ing postpartum breast involution, which is of potential
relevance since immune infiltrate may contribute to the
poor prognosis of postpartum breast cancer [29]. To





















































































Figure 5 Evidence for apoptosis and immune cell infiltration during postpartum breast involution. Aa, b. H & E stained sections showing
lactational and involutional morphology of lobules within an actively involuting postpartum breast. Ac, d. Apoptosis is evident in lobules with
involutional morphology as detected by TUNEL stain (TdT nick end labeling) (arrow). Inset shows single acini in an involutional lobule with two
apoptotic epithelial cells. B. Quantitation of TUNEL staining in lactational and involutional lobules from early involution breast tissue obtained
from six women (*P <0.0001). C. Quantification of CD45+ immune cell numbers across reproductive groups of nulliparous (N) (n = 24), pregnant
(P) (n = 7), ≤1 to ≤6 (n = 9), >6 to ≤12 (n = 7) and >12 to ≤24 months (n = 6), and >2 to ≤3 (n = 10), >3 to ≤6 (n = 13), >6 to ≤10 (n = 8) and >10 years
(n = 13) postpartum. When compared to nulliparous cases there is a significant increase in CD45+ cells during pregnancy (*P= 0.005), ≤1 to ≤6 months
(**P= 0.0002) and up to >6 to ≤12 months postpartum (***P= 0.01). D. Quantification of CD68+ macrophages by reproductive groups including
nulliparous (N) (n = 12), pregnant (P) (n = 8), and ≤6 (n = 4), >6 to ≤12 (n = 5) and >12 to ≤24 months (n = 10), and >2 to ≤3 (n = 5), >3 to ≤6 (n = 7), >6
to ≤10 (n = 7) and >10 years (n = 19) postpartum. There is a significant increase in CD68+ cells during pregnancy (*P= 0.01), ≤1 to ≤6 (**P= 0.0001), >6
to ≤12 (***P= 0.01) and up to 24 months postpartum (****P= 0.02) when compared to nulliparous cases. All error bars represent standard error of the
mean (SEM).
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http://breast-cancer-research.com/content/16/2/R31assess the duration of immune cell infiltrate, we investigated
lobular content of CD45+ and CD68+ cells by defined times
postpartum. We found that CD45+ cells were maximally el-
evated within six months postpartum and remained signifi-
cantly elevated up to twelve months postpartum compared
to the nulliparous group (P= 0.01) (n = 97) (Figure 5C). Evi-
dence for a further and gradual decline in CD45 for up to
10 years postpartum is also observed; however, a larger co-
hort is required to determine more precisely the pattern of
CD45+ cell efflux in the postpartum breast. CD68+ levelswere also maximal in the ≤6 months postpartum group
(Figure 5D), and remained elevated through ≤24 months
postpartum (P = 0.02) (n = 77) (Figure 5D), returning to
nulliparous levels by 3 years postpartum. Dual staining
revealed that approximately 60% of CD45+ cells were
CD68+ as well (data not shown). These data indicate
that leukocytes, in general, and macrophages, specifically,
persist in the postpartum gland beyond the 12 to 18 month
time frame when morphological evidence shows complete
lobule regression.
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Wound healing and inflammatory milieus are strongly
implicated in breast cancer incidence and progression
[25,28,30,34,49]. In rodents, physiologically normal post-
partum mammary gland involution has wound healing
and immunomodulatory properties and promotes breast
cancer growth, invasion and metastasis in xenograft
models [7,17,25,28,29]. Similar wound healing and im-
munologic attributes in the human breast may help ex-
plain the poor prognosis of breast cancers diagnosed within
five years of a completed pregnancy [7,18,25,28,30,36,49,50].
Here, we confirm conservation of tissue mechanisms of
postpartum mammary gland involution between rodents
and humans, including massive epithelial cell loss and acqui-
sition of immune attributes previously correlated with pro-
tumorigenic microenvironments [7,28,30]. These studies
begin to identify a narrowed time period in a postpartum
woman’s life that may represent a unique window of in-
creased breast cancer risk and progression.
In rodents, postpartum mammary gland involution is
primarily characterized by programmed apoptotic death
of the secretory mammary epithelium [19,51]. In our
premenopausal human cohort, a complete loss of the
differentiated lobules developed in preparation for lacta-
tion is observed by 18 months postpartum. This reversal
of lobular area and type composition to baseline levels is
consistent with epithelial cell death being the primary
cellular mechanism driving postpartum involution. High
levels of mammary epithelial cell apoptosis observed
in breasts within six weeks post-weaning corroborate
this hypothesis. Further, CD45+ leukocyte and CD68+
macrophage infiltration into the involuting human
breast suggests the use of wound healing-like pro-
grams to remodel the pregnant/lactating gland to its
non-secretory state. Given the evidence for immune
cell promotion of breast cancer [28,31,50,52], this im-
mune infiltrate into the involuting breast may con-
tribute to the poor prognosis of women diagnosed
postpartum.
Previously published data have shown persistence of
differentiated type 3 lobules in breasts of premenopausal
parous women [39,45-47]. Our data showing no differ-
ences in total lobule area and type composition between
nulliparous and parous cohorts are contrary to these
published data. Based on the small differences we ob-
served in type 3 lobule composition between nulliparous
and parous cohorts, we calculate that approximately 775
premenopausal breast biopsies are required to adequately
address the question of whether type 3 lobules persist in
parous women. Further, our analysis is limited in that we
have not performed gene expression studies, which have
demonstrated persistent gene expression changes consist-
ent with lobule differentiation with parity [45,53,54]. Con-
sistent with previous reports [39], we did observe adecrease in the proliferative capacity of mammary epithe-
lial cells with completed pregnancy as well as an increase
in the total number of lobules present. Additional clinical
variables that may contribute to why persistent type 3 lob-
ules were observed in previous studies but not in ours
include differences of ethnicity, basal metabolic index,
hormone based contraceptive use, and/or familial his-
tory of breast cancer.
A previous study comprising 9,000 cases encompass-
ing all ages reported age-related breast involution in ap-
proximately 8.5% of women less than 40-years-old [40].
In our premenopausal cohort, we did not identify age-
related involution. Several factors, including the nar-
rower age range investigated in our study, the exclusion
of postmenopausal cases, the relatively small size of our
cohort and differences in morphometric endpoints uti-
lized to measure lobular involution likely contribute to
differences observed between studies.
Our study design has several strengths including the
use of never-been-pregnant cases for our nulliparous
group, permitting for the first time an evaluation of
baseline breast morphology in the absence of a prior
pregnancy, including incomplete pregnancies. Our mor-
phometric analysis is also an asset, as the semi-quantitative
IHC approach permits computer generated data collection
within the entire tissue section and acquisition of continu-
ous rather than categorical data, which reduces the poten-
tial for inadvertent operator bias. Further, our study sample
size is the largest cohort to date to assess postpartum breast
involution based on verification of clinical medical records
for date of last pregnancy. Another important strength of
our study is that we have limited our analysis to premeno-
pausal women. Other studies investigating normal mam-
mary gland morphology have encompassed broader age
ranges and pre- and post-menopausal status, making it
more difficult to discern between postpartum, age-related
and menopause-induced breast involution [40,55].
A potential limitation of our study is the availability of
a single tissue specimen per case as a representative of
the whole breast specimen. To address this limitation,
we performed lobular composition analysis for three
mastectomy specimens and found that a single biopsy
can be globally representative of the entire breast tissue.
While our results confirm previous reports demonstrat-
ing some variation in lobule complexity between breast
quadrants [39], our data also support the work of others
indicating that the use of a single tissue analysis is rela-
tively representative of global tissue architecture [40,55].
Another limitation of our study is the low number of
cases consisting of true normal breast tissue in the ab-
sence of any pathological lesion. Recently, true normal,
reduction mammoplasty and benign-disease breast tis-
sues were found to differ in the process of age-related
involution, with true normal breast showing increased
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magnitude and duration of postpartum breast involution
between cancer and benign cases, suggesting that post-
partum breast involution is a dominant regression pro-
gram that occurs relatively independent of adjacent
pathology. However, repeating a postpartum breast in-
volution study in true normal tissue remains an im-
portant objective. Lastly, our cohort lacks patient ethnic
diversity and is enriched for older age mothers with low
gravidity. Published studies show that Hispanic and
African American women have younger age at first
pregnancy, higher gravidity, distinct nursing histories
[57-59], and experience a higher incidence of young
women’s breast cancer than Whites [59-61]. In order
to further investigate the feasibility of developing pre-
vention and treatment strategies targeted to the post-
partum window, it will be essential to determine if
postpartum breast involution is modified by race, re-
productive and lactation histories, as well as risk profiles.Conclusions
This study identifies postpartum breast involution in
women as a dominant window of tissue remodeling
characterized by massive loss of differentiated lobules,
apoptotic epithelial cell death and immune infiltrate as-
sociated with breast cancer progression in preclinical
models. Further research into the mechanisms of human
postpartum breast involution and its potential tumor
promoting attributes may lead to novel prevention and
treatment strategies for postpartum breast cancer. A po-
tential asset would be the limited duration of treatment
required to target this narrowed window of risk.Additional files
Additional file 1: Table S1. Clinical characteristics of cases included in
the study.
Additional file 2: Table S2. Tumor characteristics of cases included in
the study.
Additional file 3: Figure S1. Area-analysis cannot distinguish between
lobular types 1 and 2. Some type 1 lobules can occupy larger areas when
compared to smaller type 2 lobules due to variation in stromal to
epithelial ratio. Eighteen type 1 lobules and 13 type 2 lobules were
included in this analysis. All error bars represent standard error of the
mean (SEM).
Additional file 4: Figure S2. Lobular composition by breast quadrant
and cancer free cases. S2a: Lobular composition in individual breast
quadrants obtained from bilateral mastectomy specimen of three women
who were six to eight years postpartum. Each individual graph represents
morphological variation in lobular composition for upper outer (UO),
upper inner (UI), lower outer (LO) and lower inner (LI) quadrants of left
(L) and right (R) breasts for each woman. S2b: Lobular composition
across the reproductive cycle in women diagnosed with benign breast
pathology. This cancer-free cohort of nulliparous (N) (n = 5), pregnant (P)
(n = 11), lactation (L) (n = 8), >1 to ≤6 months (n = 5), >2 to ≤6 years (n = 1),
and >9 years (n = 1) postpartum cases shows similar lobular composition as
that of the total cohort (Figure 3B), suggesting that at the morphologicallevel, postpartum involution is not significantly affected by the presence of
adjacent tumor. All error bars represent standard error of the mean (SEM).
Additional file 5: Figure S3. Percent area composed of type 1, 2 and 3
lobules does not change with parity status. Percent of tissue composed
of type 1, 2 and 3 lobules shows no correlation with the number of
completed pregnancies, suggesting similar gland regression with each
round of postpartum involution.
Additional file 6: Figure S4. Type 2 and 3 lobule size does not vary
between nulliparous and parous cases. S4a. No differences are noted in
average area of type 2 lobules between >2 years parous and nulliparous
cases. S4b. The average area of type 3 lobules shows a trend towards the
area being decreased in parous breast tissue compared to nulliparous
breast issue (P = 0.06). All error bars represent standard error of the mean
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